INTRODUCTION {#S1}
============

Skeletal muscle constitutes 40%--50% of body mass in the human adult and is a key determinant of basal metabolic rate and whole-body energy metabolism. Muscle is the major consumer of glucose (nearly 80% of insulin-mediated glucose uptake) and fatty acids ([@R21]; [@R58]). It has the ability to increase its energy expenditure 20- to 30-fold during intense exercise by stimulating insulin-independent glucose uptake and by switching to higher fatty acid uptake and oxidation ([@R33]; [@R71]). Many studies suggest that enhancing energy expenditure in muscle through physical activity could be the most effective strategy for controlling obesity and diabetes, second only to caloric restriction ([@R23]). Apart from physical activity, muscle expends a significant amount of energy to maintain muscle mass through protein synthesis, repair, and regeneration. In addition to contractile function, muscle is the primary organ of heat production in most mammals through shivering and nonshivering thermogenesis, demanding a considerable amount of energy ([@R4]; [@R10]; [@R14]; [@R33]; [@R61]). Data also suggest that muscle can expend energy in the form of heat during diet-induced thermogenesis; however, the mechanisms are not fully understood ([@R9]; [@R10]; [@R15]).

Our laboratory has been exploring the role of sarcoplasmic reticulum (SR)-Ca^2+^ cycling, especially the role of sarcolipin (SLN) and the sarcoendoplasmic reticulum Ca^2+^ ATPase (SERCA) pump in nonshivering thermogenesis (NST). Although SERCAmediated ATP hydrolysis is generally coupled to Ca^2+^ transport, we and others have shown that binding of SLN within the SERCA-transmembrane groove promotes uncoupling of SERCA Ca^2+^ transport from ATP hydrolysis; by this mechanism, SLN increases futile SERCA activity, ATP hydrolysis, and thus heat production ([@R35]; [@R48], [@R49]; [@R55]; [@R59]; [@R67]). Using genetically engineered SLN mouse models, we previously reported that SLN plays an important role in muscle thermogenesis and energy metabolism ([@R10]; [@R15]). Loss of SLN in muscle predisposes mice to develop hypothermia and failure to maintain whole-body temperature during cold exposure. Our studies also revealed that mice lacking SLN were prone to diet-induced obesity, whereas overexpression of SLN in fast and slow twitch fibers led to increased energy expenditure and resistance against high-fat diet-induced obesity ([@R37]; [@R56]). Although these studies implicate SLN as an important regulator of muscle thermogenesis and energy expenditure, the detailed mechanism of how SLN programs and orchestrates oxidative metabolism is not understood. Therefore, in this study, we set out to address the mechanistic basis of SLN signaling both *in vivo* and in primary muscle cells derived for *Sln* knockout (KO) and wild-type (WT) mice. A major objective of this study was to determine the role of SLN in programming mitochondrial phenotype and enhancing fatty acid oxidation in skeletal muscle.

RESULTS {#S2}
=======

SLNRegulates Mitochondrial Biogenesis and theSwitch toward Increased Oxidative Metabolism during Muscle Development {#S3}
-------------------------------------------------------------------------------------------------------------------

SLN expression is induced severalfold during early neonatal stages of muscle development (in both fast and slow twitch muscle), but its role is not well understood. The neonatal stage is precarious in a newborn's life, with a significant demand for energy to maintain thermogenesis and survive cold. Furthermore, the muscle is undergoing significant growth, differentiation, and maturation due to increased physical activity. To understand the role of SLN in neonatal physiology, we first investigated the relevance of SLN to mitochondrial biogenesis and oxidative metabolism in neonatal muscle of WT and *Sln*-KO mice. SLN expression peaks around birth and continues to be expressed at high levels in all skeletal muscles during the first 10 days of neonatal development ([@R7]; [@R43], [@R44]) ([Figure 1A](#F1){ref-type="fig"}). By day 15 postnatally, SLN expression is downregulated in mature glycolytic muscles, including quadriceps, extensor digitorum longus (EDL), and tibialis anterior (TA), but continues to be expressed in oxidative and/or slow twitch muscle, including soleus, red gastrocnemius, and diaphragm ([@R43], [@R44]). This raised the possibility that SLN is important for maintaining the oxidative metabolic phenotype in muscle. Loss of SLN had no effect on muscle fiber size ([Figure S1A](#SD1){ref-type="supplementary-material"}) and or the expression level of major contractile and SR proteins, including SERCA, calsequestrin 1 and 2 (CASQ1 and CASQ2), muscle α-actin, and α-actinin ([Figure 1B](#F1){ref-type="fig"}).

We next studied how loss of SLN expression affected muscle oxidative capacity in isolated quadriceps muscle from WT and *Sln*-KO mice (10 days old) using high-resolution respirometry. In *Sln*-KO muscle compared to WT, there was a significant decrease in fatty acid (palmitate)-supported oxygen consumption and a significant reduction in succinate-induced maximal respiration, a sign of reduced fatty acid oxidation ([Figure 1C](#F1){ref-type="fig"}). This is supported by a significant reduction in mtDNA content ([Figure 1D](#F1){ref-type="fig"}) and a drastic reduction in succinate dehydrogenase (SDH) activity in the *Sln*-KO muscle ([Figure 1E](#F1){ref-type="fig"}), indicative of decreased oxidative capacity. Expression of mitochondrial oxidative phosphorylation (OXPHOS) proteins ([Figure 1F](#F1){ref-type="fig"}) and enzymes involved in lipid metabolism, including lipoprotein lipase (LPL), carnitine palmitoyltransferase-1 mitochondrial (CPT1-M), long-chain acyl-coenzyme A (CoA) dehydrogenase (LCAD), hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta (HADHB), citrate synthase, and adenine nucleotide translocator (ANT1/2), in *Sln*-KO muscle compared to WT ([Figure 1G](#F1){ref-type="fig"}). In addition, electron microscopy of *Sln*-KO muscle revealed alteration in mitochondrial morphology, with fewer cristae of smaller length and width ([Figures S1B and S1C](#SD1){ref-type="supplementary-material"}). However, the expression of genes involved in mitochondrial dynamics, including fusion and fission, was not significantly altered ([Figures S1D and S1E](#SD1){ref-type="supplementary-material"}). Proteins involved in mitochondrial fusion and fission were higher when normalized to mitochondrial protein VDAC ([Figures S1F and S1G](#SD1){ref-type="supplementary-material"}). These data suggest that loss of SLN leads to decreased mitochondrial mass but increased mitochondrial dynamics in muscle. We next investigated the autophagy by performing western blotting of LC3 ([Figures S1H and S1I](#SD1){ref-type="supplementary-material"}) and immunostaining with LC3 and COX4-I1 antibodies ([Figures S1J and S1K](#SD1){ref-type="supplementary-material"}). The LC3-II/LC3-I ratio, which is an indicator of increased autophagy, is greater in KO muscle ([Figures S1H and S1I](#SD1){ref-type="supplementary-material"}). Similarly, KO muscle showed higher LC3 staining when normalized with mitochondrial COX4-I1 staining ([Figures S1J and S1K](#SD1){ref-type="supplementary-material"}).

To our surprise, the 10-day-old *Sln*-KO quadriceps (quads) muscle expressed higher levels of glycolytic enzymes, including phosphofructokinase 1 (PFK1), hexokinase II (HKII), pyruvate kinase muscle (PKM2), and pyruvate dehydrogenase (PDH), which suggest that *Sln*-KO muscle primarily relies on glycolytic metabolism to compensate for decreased fatty acid utilization ([Figure 1H](#F1){ref-type="fig"}). There was an activation of 5' adenosine monophosphate-activated protein (AMP) kinase, alpha (AMPKα) (increased phospho-AMPKα level) in *Sln*-KO quads, indicating a compensatory mechanism to increase energy production ([@R39]; [@R42]) ([Figure 1H](#F1){ref-type="fig"}). These data suggest that SLN is essential for the metabolic switch toward increased fatty acid oxidation in developing muscle. However, quads and gastrocnemius muscle of 10-day-old neonatal *Sln*-KO mice did not show alterations in the expression of myosin isoforms and fiber-type composition ([Figures S1L--S1N](#SD1){ref-type="supplementary-material"}).

We investigated whether loss of SLN affected oxidative metabolism in soleus muscle of adult mice, which expresses SLN throughout life. In rodents, soleus muscle contains a mixture of both fast oxidative fibers, expressing myosin heavy-chain type IIA (MHC-IIA), and slow twitch fibers, containing the myosin heavy-chain type I (MHC-I) isoform ([@R46]), with higher mitochondrial content. Our data show that loss of SLN does not alter mtDNA content in soleus muscle ([Figure 1I](#F1){ref-type="fig"}). Western blot analyses show that the expression level of mitochondrial OXPHOS proteins is not altered in *Sln*-KO soleus compared to WT ([Figure 1J](#F1){ref-type="fig"}); however, there is a reduction in enzymes involved in lipid metabolism (LPL, CPT1-M, LCAD, and HADHB) ([Figure 1K](#F1){ref-type="fig"}) and the ability to oxidize fatty acid ([Figure 1L](#F1){ref-type="fig"}). Enzymes involved in glucose metabolism were not affected ([Figure 1M](#F1){ref-type="fig"}). SDH activity staining confirmed that loss of SLN in soleus muscle decreases its oxidative capacity ([Figure 1N](#F1){ref-type="fig"}). Surprisingly, loss of SLN does not affect the composition of MHC-IIA and MHC-I fibers in soleus muscle ([Figure 1O](#F1){ref-type="fig"}). These data suggest that SLN is critical for maintaining muscle oxidative metabolism, but not fiber-type switching.

SLN Overexpression in Fast Twitch Glycolytic Muscle Reprograms Mitochondria to Increase Fat Oxidation and Resists against Diet-Induced Lipotoxicity {#S4}
---------------------------------------------------------------------------------------------------------------------------------------------------

Because SLN expression is downregulated in adult glycolytic muscle, we asked whether transgenic expression of SLN in glycolytic muscle promotes oxidative metabolism using the skeletal muscle-specific SLN overexpression (*Sln*^*OE*^) mouse model ([@R56]). Overexpression of SLN in glycolytic muscle (TA, quads, and gastrocnemius) did not result in fibertype switching, and the numbers of oxidative and glycolytic muscle fibers were similar to those of WT muscle ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}). In addition, SLN overexpression did not affect mtDNA content ([Figure 2A](#F2){ref-type="fig"}) or the expression level of OXPHOS proteins in TA muscle ([Figure 2B](#F2){ref-type="fig"}). However, SLN overexpression caused an increase in fatty acid transport proteins, especially CD36, CPT1-M, LPL, and mitochondrial enzymes involved in fatty acid oxidation, like LCAD and HADHB ([Figure 2C](#F2){ref-type="fig"}). Furthermore, glycolytic muscle fibers overexpressing SLN showed higher fatty acid oxidation as measured by oxidation of fatty acid substrates (palmitoylCoA + carnitine) in comparison to *Sln*-KO muscle ([Figure 2D](#F2){ref-type="fig"}). Expression of fusion and fission genes was not significantly different ([Figure S1C](#SD1){ref-type="supplementary-material"}). However, when expression of fusion and fission proteins was normalized with VDAC protein levels, *Sln*^OE^ muscle showed a lower abundance of mitochondrial dynamic proteins ([Figures S2D and S2E](#SD1){ref-type="supplementary-material"}).

We next investigated whether higher SLN expression and activity can prevent high-fat diet (HFD)-induced metabolic abnormalities in muscle. HFD feeding induced a significant increase in mtDNA copy number ([Figure 2E](#F2){ref-type="fig"}), the expression of OXPHOS protein complexes ([Figure 2F](#F2){ref-type="fig"}), and enzymes involved in fatty acid metabolism in glycolytic muscle (TA) of *Sln*^OE^ compared to WT muscle ([Figure 2G](#F2){ref-type="fig"}). This increase in mitochondrial metabolic enzymes was supported by a significant increase in fatty acid oxidation (palmitatoylcarnitine) in *Sln*^*OE*^ muscle ([Figure 2H](#F2){ref-type="fig"}). TA muscle of *Sln*^*OE*^ mice did not show lipid accumulation compared to WT muscle (very low SLN expression) ([Figure 2I](#F2){ref-type="fig"}) and *Sln*-KO muscle ([Figure S2F](#SD1){ref-type="supplementary-material"}). Conversely, *Sln*-KO soleus showed significant accumulation of lipid droplets compared to WT soleus (high SLN expression) ([Figure 2J](#F2){ref-type="fig"}), a sign of decreased fat utilization, whereas muscle overexpressing SLN did not show signs of lipid accumulation. Furthermore, we observed a lower intramuscular concentration of ceramide, diacylglycerides (DAGs), and acylcarnitines in *Sln*^*OE*^ muscle compared to WT ([Figure 2K](#F2){ref-type="fig"}). Studies have shown that excess accumulation of these lipid intermediates contributes to lipotoxicity and insulin resistance in skeletal muscle ([@R50]; [@R54]; [@R57]); therefore, we next investigated the muscle glucose uptake and glucose clearance in live mice using hyperinsulinemic-euglycemic clamp ([Figure 2L](#F2){ref-type="fig"}). As expected, *Sln*^*OE*^ mice displayed a higher rate of muscle glucose uptake and clearance compared to WT mice, suggesting enhanced muscle insulin sensitivity. Conversely, *Sln*-KO mice showed a lower rate of muscle glucose uptake and clearance compared to WT mice, suggesting insulin resistance in *Sln*-KO muscle ([Figure S2G](#SD1){ref-type="supplementary-material"}). Altogether, these findings strongly suggest that increased SLN expression in muscle reprograms mitochondria, enhances fatty acid oxidation, and protects against lipotoxicity, thus improving insulin sensitivity.

SLN Recruits PGC1α to Activate Mitochondrial Biogenesis {#S5}
-------------------------------------------------------

To explore the mechanistic details of how SLN regulates mitochondrial phenotype, we took advantage of primary muscle cell cultures derived from *Sln*-KO and WT mice ([Figure 3A](#F3){ref-type="fig"}). SLN is not expressed in myoblast, but its expression is relatively high in differentiating WT myotubes ([Figure 3B](#F3){ref-type="fig"}). Both WT and *Sln*-KO myotubes expressed normal levels of contractile (α-actinin and α-actin) and SR-Ca^2+^ transporter SERCA2 ([Figure 3C](#F3){ref-type="fig"}). However, *Sln*-KO myotubes showed a significant decrease in mitochondrial content, as observed by lower mtDNA copy number ([Figure 3D](#F3){ref-type="fig"}) and decreased expression of OXPHOS protein complexes ([Figure 3E](#F3){ref-type="fig"}). However, the expression of genes involved in mitochondrial dynamics, including fusion and fission, was not significantly altered ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}). *Sln*-KO myotubes showed a lower rate of fatty acid oxidation and a decreased oxygen consumption rate (OCR), supporting the lower mitochondrial content (Figures [3F](#F3){ref-type="fig"} and[3G](#F3){ref-type="fig"}), whereas the rate of glycolysis and glycolytic capacity (as measured by the extracellular acidification rate \[ECAR\]) of *Sln*-KO myotubes was higher than that of WT myotubes ([Figures S3C and S3D](#SD1){ref-type="supplementary-material"}). We next tested whether re-expression of SLN through adenoviral gene transfer could rescue the mitochondrial phenotype in *Sln*-KO myotubes ([Figure 3H](#F3){ref-type="fig"}). Re-expression of SLN in *Sln*-KO myotubes restored mtDNA content ([Figure 3I](#F3){ref-type="fig"}), respiratory capacity (OCR) ([Figure 3J](#F3){ref-type="fig"}), and PGC1α expression to WT control levels ([Figure 3K](#F3){ref-type="fig"}).

In WT myotubes, PGC1α expression increased progressively during differentiation ([Figure 3L](#F3){ref-type="fig"}), whereas loss of SLN caused a decrease in the expression level of PGC1α, PPARδ, and TFAM ([Figures 3L and 3M](#F3){ref-type="fig"}). PGC1α is the master regulator of mitochondrial biogenesis, especially in muscle. Therefore, we next addressed whether SLN mediates its effect through upregulation of PGC1α by using small interfering RNA (siRNA)-mediated knockdown (KD) of PGC1a in WT and *Sln*-KO primary myotubes. As previously reported, PGC1α KD in WT myotubes decreased mtDNA copy number, OXPHOS protein expression, and OCR ([Figures 3N--3P](#F3){ref-type="fig"}). We tested whether the rescue of *Sln*-KO myotubes by adenoviral SLN gene transfer is mediated through PGC1α. We show that knocking down PGC1α blunted the effect of adenoviral SLN (Ad-SLN) on mitochondrial biogenesis, including mtDNA copy number, OXPHOS protein expression, and OCR ([Figures 3N--3P](#F3){ref-type="fig"}; [Figure S3C](#SD1){ref-type="supplementary-material"}). Conversely, overexpression of PGC1α in *Sln*-KO myotubes partially rescued mitochondrial biogenesis compared to WT myotubes ([Figure 3Q](#F3){ref-type="fig"}). These experiments demonstrate that SLN recruits PGC1α to promote mitochondrial biogenesis.

SLN Alters Cytosolic Ca^2+^ Transients and Activates Ca^2+^-Dependent Signaling Pathways {#S6}
----------------------------------------------------------------------------------------

To determine whether SLN affected cytosolic Ca^2+^ transients, we performed Ca^2+^ imaging using green fluorescent dye (Fluo-4) in C2C12 myotubes expressing high levels of SLN through Ad-SLN gene transfer ([Figures 4A--4C](#F4){ref-type="fig"}). Myotubes expressing SLN showed a higher percentage of cytosolic Ca^2+^ transients (\>18%) compared to nontransfected (NT) myotubes in response to caffeine-induced Ca^2+^ release. The Ad-SLN-transfected myotubes show an increase of \>2 s in the average time of fluorescence in the cytosol, measured at 50% of the peak; these myotubes also showed a slower decay of the fluorescence in the cytosol, as measured by the slope (0.088 interval \[int\]/ms) compared to NT (0.090 int/ms) ([Figure 4C](#F4){ref-type="fig"}). These data indicate a slower Ca^2+^ removal by SERCA in the presence of SLN. However, fluorescence measured 60 s post-stimulation with caffeine showed higher levels of cytosolic Ca^2+^ in Ad-SLN-transfected myotubes (\>28%) compared to NT myotubes ([Figure 4C](#F4){ref-type="fig"}). Cytosolic Ca^2+^ remained higher over the course of the experiment in Ad-SLN-transfected myotubes compared to NT control myotubes. These data suggest that SLN shapes cytosolic Ca^2+^dynamics byincreasing theduration of Ca^2+^transients inthe cytosol, which activates Ca^2+^-dependent signaling mechanisms.

To determine whether SR-Ca^2+^ cycling is a prerequisite for SLN signaling, we manipulated SR-Ca^2+^ release in myotubes using caffeine to sensitize ([@R20]) and dantrolene to inhibit RYR1, the primary Ca^2+^ release channel in skeletal muscle SR ([@R17]). Treatment with 3.5 mM caffeine resulted in an increase in phosphorylated Ca2+/calmodulin-dependent protein kinase II (pCamKII) activation and Mef2c expression in WT myotubes, but not in *Sln*-KO myotubes ([Figure 4D](#F4){ref-type="fig"}). Caffeine treatment of WT myotubes increased mitochondrial biogenesis, as measured by mtDNA content ([Figure 4E](#F4){ref-type="fig"}), PGC1α, ([Figure 4F](#F4){ref-type="fig"}), and PPARδ, TFAM, and metabolic enzymes ([Figure 4G](#F4){ref-type="fig"}), whereas *Sln*-KO myotubes failed to show an increase in mitochondrial biogenesis ([Figures 4D--4G](#F4){ref-type="fig"}). Furthermore, caffeine-treated WT myotubes showed a significant increase in mitochondrial respiration, but *Sln*-KO myotubes showed a poor response to caffeine treatment ([Figure 4H](#F4){ref-type="fig"}). In contrast, inhibition of SR-Ca^2+^ release by dantrolene treatment (10 μM) decreased CamKII activation, mitochondrial biogenesis ([Figures 4I--4L](#F4){ref-type="fig"}), and respiratory capacity only in SLN-expressing myotubes ([Figure 4M](#F4){ref-type="fig"}). We show that inhibition of CamKII activation by pretreatment with KN93 decreased mitochondrial biogenesis and respiratory capacity in WT myotubes. In contrast, SLN re-expression in *Sln*-KO myotubes rescued the phenotype, as evident by increased CamKII activity, mtDNA content, and respiration ([Figures 4N--4P](#F4){ref-type="fig"}). Altogether, these data demonstrate that SLN is essential for the Ca^2+^-dependent increase in mitochondrial biogenesis and this directly depends on SR-Ca^2+^ cycling and recruitment of the CamKII-PGC1α axis ([Figure 4Q](#F4){ref-type="fig"}).

DISCUSSION {#S7}
==========

SLN is an important regulator of the SERCA pump, which is expressed exclusively in striated muscle of all mammals, including humans ([@R45]; [@R47]; [@R62]). Studies have shown that SLN binds to SERCA in a Ca^2+^-sensitive manner and its binding can lead to uncoupling of SERCA pump activity ([@R48], [@R49]; [@R55]). However, the molecular basis of SLN-SERCA interaction is still under intense investigation. Studies have shown that SLN binding to SERCA does not interfere with ATP hydrolysis of the pump but prevents Ca^2+^ transport into the SR lumen, thus promoting slippage of Ca^2+^ back to the cytosol ([@R35]; [@R48], [@R49]). By this mechanism, SLN promotes futile cycling of the pump, increases heat generation, and plays an important role in muscle thermogenesis ([@R53]). Unlike UCP1 in brown adipose tissue (BAT), which dissipates proton gradient (decreasing proton motive force for ATP generation) and generates heat ([@R13]), SLN creates energy demand via futile SERCA activity, increased ATP hydrolysis, and heat production responsible for muscle NST. Using genetically engineered SLN mouse models, we have shown that SLN is important for adaptive thermogenesis, including cold and diet-induced thermogenesis ([@R10]). Previously, we reported that an increase in the SLN-toSERCA ratio due to SLN overexpression in muscle can promote increased energy expenditure and provide resistance against diet-induced obesity ([@R37]; [@R56]). In the present study, we investigated the mechanistic basis for the SLN-mediated increase in oxidative metabolism in muscle. We specifically studied how SLN affects mitochondrial phenotype *in vivo* and in primary muscle myotubes. Our studies provide a fundamental framework for the understanding of how regulation of SR-Ca^2+^ cycling can be a powerful signal to regulate mitochondrial oxidative capacity and energy metabolism in muscle.

In this study, we addressed the physiological relevance of high SLN expression during neonatal muscle development in both fast twitch (glycolytic) and slow twitch (oxidative) muscle. Our results point out that SLN is critical for mitochondrial biogenesis and that loss of SLN leads to decreases in mitochondrial content and fatty acid oxidation. In addition, the mitochondria in *Sln*-KO muscle had fewer cristae and expressed lower levels of enzymes involved in fatty acid transport and oxidation. *Sln*-KO muscle shows upregulation of the glycolytic pathway as a compensatory mechanism. These data suggest that SLN plays a critical role in neonatal muscle to orchestrate a metabolic switch toward increased lipid oxidation, a signature of mature muscle mitochondria ([@R32]; [@R51]). These and other published data suggest that SLN expression is essential to meet the thermogenic and metabolic demand for survival of the neonates ([@R41]; [@R52]).

Our studies also highlight that a loss of SLN in oxidative and/or slow twitch muscle compromised oxidative capacity and that this is largely due to reduced expression of fatty acid transporters and mitochondrial oxidative enzymes. However, loss of SLN did not affect the fiber-type composition or myosin expression in slow twitch soleus muscle. The most interesting finding of this study was that SLN overexpression in glycolytic muscle induced an oxidative metabolic phenotype by reprogramming mitochondria without affecting the fiber-type composition. The mitochondria of *Sln*^*OE*^ muscles contained higher levels of fatty acid transporters (CPT1-M) and enzymes involved in beta-oxidation (LCAD/HADHB). In addition, proteins involved in fatty acid import to cytosol (CD36) and lipolysis (LPL) were increased to synchronize increased oxidative metabolism. These results and data from neonatal muscle suggest that SLN is critical for maintaining the oxidative capacity of the muscle.

It has been shown that dysfunction or decrease in muscle oxidative metabolism leads to increased lipid accumulation, causing lipotoxicity and insulin resistance ([@R3]; [@R29]). We found that loss of SLN compromised mitochondrial function and its ability to enhance fat oxidation in muscle. When challenged with HFD, the *Sln*-KO muscle showed decreased fatty acid oxidation, increased intramuscular lipid accumulation, and higher concentration of toxic lipid derivatives (ceramide, DAGs, and acylcarnitines). In contrast, overexpression of SLN increased fat oxidation but showed no evidence of intramuscular lipid accumulation and toxic lipid derivatives in glycolytic muscle. The observed lipid accumulation in *Sln*-KO muscle is likely due to decreased energy expenditure and lower fat oxidizing capacity, whereas SLN overexpression increased energy expenditure and reprogrammed the muscle metabolism to enhance fatty acid oxidation. Several studies have shown that lipotoxicity is tightly linked to muscle insulin resistance and impairment of insulin-mediated glucose uptake ([@R1]; [@R12]; [@R54]). Our data demonstrate that overexpression of SLN improved insulin sensitivity, whereas *Sln*-KO mice showed a sign of insulin resistance. These data collectively suggest that SLN plays a prominent role in regulating muscle oxidative capacity, thereby preventing excess fat accumulation and insulin resistance.

An important objective of this study was to understand the mechanistic basis of how SLN signals to program mitochondrial biogenesis and oxidative metabolism in muscle. Previous studies have shown that SLN affects SR-Ca^2+^ cycling and modifies cytosolic Ca^2+^ during muscle contraction ([@R56]; [@R60]). We show here that SLN interaction with SERCA alters cytosolic Ca^2+^ transients, leading to activation of Ca^2+^-dependent signaling pathways, especially CamKII, and increased PGC1α expression. Published studies and results from this study demonstrate that an increase in cytosolic Ca^2+^ transients leads to activation of Ca^2+^ signaling pathways and recruitment of PGC1α to promote mitochondrial biogenesis ([@R18]; [@R30]; [@R36]; [@R38]; [@R68]; [@R69]). Another key transcription factor, transcription factor EB (TFEB), because of its calcium-dependent regulation, may also be involved in this SLN-dependent signaling pathway ([@R36]). This is especially relevant in light of the decreased TFEB phosphorylation due to increased calcineurin activity in *Sln*^*OE*^ muscle. In this study, we provide evidence that SR-Ca^2+^ cycling acts as a strong signal to modulate mitochondrial biogenesis. By manipulating SR-Ca^2+^ release with caffeine and dantrolene, we demonstrate that activation of PGC1α depends on SR-Ca^2+^ cycling and SLN/SERCA interaction. Our data suggest that SLN functions to coordinate energy demand with increased energy production by enhancing mitochondrial function and metabolism through calcium signals. Consistent with this model, our results from mouse models also suggest that a higher SLN-to-SERCA ratio leads to increased mitochondrial biogenesis by creating higher energy demand.

Increasing oxidative metabolism and muscle energetics is an attractive strategy to control obesity and metabolic syndrome. It has been reported that muscle mitochondrial biogenesis can be activated by administering AICAR (an AMPK activator) or GW 1516 (a PPARδ activator) ([@R39]). Although these compounds are effective for increasing mitochondrial biogenesis, they do not create energy demand ([@R65]). Unlike these compounds, SLN-activated mitochondrial biogenesis appears to be a physiological homeostatic response, linking energy demand with energy production. Moreover, by increasing energy demand in muscle through modulation of SERCA activity, SLN acts as an exercise mimetic to increase energy expenditure. In addition, SLN activity can be enhanced by activity (e.g., exercise) and by adaptive thermogenesis in response to cold or caloric excess ([@R34]; [@R40]; [@R52]). Most importantly, we have not found adverse effects due to SLN overexpression in muscle. SLN overexpression mice show a higher endurance capacity and improved muscle performance by increasing oxidative capacity ([@R56]).

In summary, our studies suggest that SLN acts as a dual regulator of muscle metabolism: (1) by promoting futile SERCA pump activity, it creates energy demand, playing a role in muscle thermogenesis, and (2) by altering cytosolic Ca^2+^, SLN signals to activate mitochondrial biogenesis through CamKII/PGC1α signaling. Hence, we suggest that SLN effectively functions to integrate increased energy demand with increased mitochondrial ATP production and that manipulation of SR-Ca^2+^ cycling through SLN should be considered a strategy to promote mitochondrial health and whole-body energy metabolism.

EXPERIMENTAL PROCEDURES {#S8}
=======================

Animals {#S9}
-------

The generation of the *Sln*-KO mouse model ([@R8]) and *Sln*^*OE*^ mouse model ([@R56]) has been described previously. Animal procedures were approved by the Sanford Burnham Prebys Medical Discovery Institute Animal Care and Use Committee (SBP-IACUC) and conducted in accordance with the Guide for the Care and Use of Laboratory Animals. All animal experiments were performed at the regular housing temperature (22°C ± 1°C).

HFD Studies {#S10}
-----------

*Sln*^*OE*^, *Sln*-KO, and WT mice (8 weeks old, n = 12) were fed a HFD (45% calories from fat) (Research Diet) for 12 weeks.

*In Vivo* Glucose Uptake Using Hyperinsulinemic-Euglycemic CLAMP {#S11}
----------------------------------------------------------------

Glucose clamping was done as previously described ([@R5], [@R6]; [@R19]).

High-Resolution Respirometry Using Oroboros Oxygraph {#S12}
----------------------------------------------------

Measurement of mitochondrial function (oxygen consumption) in permeabilized (with saponin) muscle fibers was performed at 37°C using Oxygraph 2K (Oroboros, Austria) ([@R22]). Mitochondrial respiration in permeabilized (with digitonin) primary myotubes was measured as described earlier ([@R16]). Fatty acid-supported mitochondrial respiration was measured following the addition of saturating concentrations of palmitate + malate (2 M) and glutamate (500 mM). Maximal respiration supported by electron flux through complex I was measured with the addition of ADP (500 mM). State 3 respirations (maximal coupled respirations) were achieved by adding saturating concentrations of succinate (500 mM). Steady-state O~2~ flux for each respiratory state was determined and normalized to fiberbundle dry weight using Datlab 6 software.

Histology and Electron Microscopy of Muscle Tissues {#S13}
---------------------------------------------------

H&E, oil red O, SDH, and myosin heavy chain (MHC) staining were performed as previously described ([@R2]; [@R25]; [@R26]; [@R70]). The fiber typing was done using the antibodies MHC-I (red, BA-D5), MHC-IIA (yellow, 2F7), MHC2x (black, unstained), and MHC2b (green, 10F5) from Developmental Studies Hybridoma Bank (East Iowa City, IA) ([@R66]). Autophagy marker LC3A/B antibody (Cell Signaling Technology, 4108) and mitochondrial marker COX4-I1 antibody (R&D Systems, AF5814) were used for co-localization staining in muscle sections. The images were captured using Aperio Scanscope (Leica). For transmission electron microscopy, skeletal muscles were fixed with 1% glutaraldehyde solution. The muscle samples were cut and processed as described in [@R11] and [@R70]. Electron micrographs were obtained using a Tecnai G2 Spirit transmission electron microscope (FEI, Hillsboro, OR). ImageJ (NIH) was used to quantify images.

Quantification of mtDNA Copy Number {#S14}
-----------------------------------

The levels of NADH dehydrogenase subunit 1 (Nd1, mtDNA) were quantified (using qPCR) and normalized to the levels of LPL (genomic DNA) ([@R31]). The primers were mtDNA Nd1 (mt-Nd1) forward (Fw), 5'-CCCATTCGC GTTATTCTT-3'; mt-Nd1 reverse (Rv), 5'-AAGTTGATCG TAACGGAAGC-3'; LPL Fw, 5'-GGATGGACGGTA AGAGTGATTC-3'; and LPL Rv, 5'-ATCCAAGGGTAGCAGACAGGT-3'.

Gene Expression Analysis {#S15}
------------------------

Total RNA was isolated from the myotubes using the TRIzol reagent in accordance with the manufacturer's guidelines. 1 μg of RNA was reverse transcribed using the Maxima first strand cDNA synthesis kit (QIAGEN). Gene expression analysis was performed on Roche Real-Time PCR System using custom-designed primers. The list of primers is provided in [Table S1](#SD1){ref-type="supplementary-material"}.

Lipidomics {#S16}
----------

Multidimensional mass spectrometry-based shotgun lipidomics methodology was used to measure and characterize the lipid species (ceramides, DAGs, and acylcarnitines) in skeletal muscle. The lipids were extracted from muscle by a modified Bligh and Dyer procedure and measured as previously described ([@R63]; [@R64]).

Primary Muscle Cell Culture {#S17}
---------------------------

Primary muscle cells were isolated from skeletal muscles as previously described ([@R24]). For differentiation, cells were washed with PBS, refed with 2% horse serum/DMEM differentiation medium, and then refed daily. Primary myoblasts were infected with an adenovirus overexpressing GFP, SLN, GFP short hairpin RNA (shRNA), or PGC1α shRNA as previously described ([@R25]; [@R28]). Twelve hours after infection, cells were differentiated by switching to differentiation medium. Differentiated myotubes were treated with caffeine (3.5 mM), dantrolene (10 μM), or KN93 (1 μM) for 48 hr.

Live-Cell Ca^2+^ Imaging {#S18}
------------------------

For confocal imaging of Ca^2+^ dynamics, C2C12 cells were seeded on glass-bottom dishes (MatTek). After 3 days of differentiation, myotubes were infected with adenovirus-containing SLN gene in differentiation medium (DM) for 4 hr. SLN-transfected and NT myotubes were washed with Krebs-Ringer-HEPES (KRH) buffer (125 mM NaCl, 5 mM KCl, 1.2 mM KH~2~PO~4~, 6 mM glucose, 1.2 mM MgCl~2~, 25 mM HEPES) and loaded with Fluo-4 acetoxymethyl (AM) (5 μM; Invitrogen, F14201) for 45 min, followed by washes and incubation with KRH for 30 min. For the evaluation of Ca^2+^ cycling in myotubes, fluorescence intensity was monitored by time-lapse microscopy at 60 fps for up to 3 min after the addition of 10 mM caffeine (final concentration, 500 μM), using a laser confocal microscope with a resonant scanner (Nikon A1R, Nikon Instruments, Melville, NY). Before any stimulation, basal Fluo-4 fluorescence was imaged with a Galvano scanner to study resting calcium levels. Processing and analysis of the acquired images were carried out using Nikon NIS-Elements AR Analysis 4.40 software. Cytosolic Ca^2+^ oscillations were measured at 50% of the peak fluorescence using the time measurement tool in selected multi-regions of interest (multi-ROIs). The SR-Ca^2+^ uptake rate was measured by analyzing the curve slope at 50% of the peak (variation of fluorescence intensity over time). Quantitative analysis was done under a 20× objective lens, and approximately 35--45 cells were scored for each experimental condition in five separate analyses (n = 5).

OCR and ECAR Using a Seahorse Flux Analyzer {#S19}
-------------------------------------------

The mitochondrial OCR and ECAR were measured as a function of mitochondrial respiration using a Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience). Before assay, the myotubes were washed and incubated with DMEM without bicarbonate in a CO~2~-free incubator for 1 hr at 37°C. For OCR measurements, oligomycin (5 mg/mL), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (5 mM), and rotenone (1 mM) were successively injected in the cell assay plate. For ECAR measurement, glucose (10 μM), oligomycin (1.0 μM), and 2-Deoxy-glucose (2-DG) (50 mM) were successively injected in the cell assay plate. OCR and ECAR were automatically calculated and recorded by the Seahorse XF96 software Wave.

Western Blotting {#S20}
----------------

Expression levels of mitochondrial and other signaling proteins were determined by western blotting as previously described ([@R27]). Skeletal muscle tissues were homogenized in ice-cold homogenization buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl~2~, 5 mM Na~4~O~7~P~2~, 10 mM NaF, 100% nonidet P-40, 10% glycerol, 20 mM Tris \[pH 7.8\], 1 mM EDTA, 0.2 mM PMSF, 0.5 mM Na~3~VO~4~, protease inhibitor cocktail). After electrophoresis, proteins were transferred to 0.2 or 0.45 μM nitrocellulose membranes. Membranes were blocked for nonspecific binding at room temperature (RT) for 1 hr using LI-COR blocking buffer + tris buffered saline (TBS)-Tween 20 (TBS-T) (1:1 v/v). Membranes were probed with primary antibodies for either 2 hr at RT or overnight at 4°C. The following primary antibodies were used: SLN (Millipore, ABT13), α-actin (Abcam, ab28052), SERCA1a and SERCA2b (custommade antibodies, YenZym, San Francisco), CASQ1 (Fisher, MA3913), CASQ2 (Santa Cruz, sc390999), α-actinin (Sigma-Aldrich, A7811), mitoOXPHOS antibody cocktail (Abcam, ab110413), LPL (Abcam, ab21356), CPT1-M (Alpha Diagnostics, CPT1M11-S), LCAD (Abcam, ab128566), HADHB (Novus Biologicals, NBP1--82609), ANT1/2 (Santa Cruz, sc-9300), citrate synthase (Santa Cruz, sc-390693), HKII (Millipore, AB3279), PFK1 (Santa Cruz, sc67028), GAPDH (Santa Cruz, sc-25778), PKM2 (Santa Cruz, sc-292640), PDH (Cell Signaling Technology \[CST\], 2784), pAMPK (CST, 2535), AMPK (CST, 5831), CD36 (Santa Cruz, sc-9154), TFAM (Santa Cruz, sc-23588), PGC1α (CST, 2178), PPARδ (Abcam, ab137724), p-CamKII alpha (Santa Cruz, sc12886), CamKII alpha (Santa Cruz, sc-13141), and Mef2c (Abcam, ab70961). After being washed with 0.05% TBS-T, blots were probed with the appropriate infrared (IR)-linked secondary antibody (IRDye, LI-COR) for 1 hr at RT and then washed again with 0.05% TBS-T. Finally, membranes were scanned using a LI-COR Odyssey scanner.

Data Analysis {#S21}
-------------

Statistical analyses were performed using GraphPad Prism software (v.6.0). All data are expressed as means ± SEM. Where appropriate, a Student's t test or an ANOVA followed by a Tukey or Bonferroni post hoc test was performed. The following levels of significance were used: \*p = 0.01, \*\*p = 0.001, and \*\*\*p = 0.0001.

Supplementary Material {#SM1}
======================

This work was supported, in part, by NIH grant R01 DK098240--01 and by American Diabetes Association Basic Science Research Award (7--13-BS-131) to M.P. NIH grant R01 HL 058493 to D.P.K. is acknowledged. We thank the SBP Medical Discovery Institute's Cardiometabolic Phenotyping Core for *in vivo* glucose uptake studies and John Shelly for histological staining and electron microscopy. We thank Dr Xianlin Han's lab for isolation and quantification of intramuscular lipids species. Technical help from Andrea Bergano and administrative support by Lorenzo Thomas are also acknowledged.

DECLARATION OF INTERESTS

The authors declare no competing interests.

SUPPLEMENTAL INFORMATION

Supplemental Information includes three figures and one table and can be found with this article online at <https://doi.org/10.1016/j.celrep.2018.08.036>.

![SLN Regulates the Mitochondrial Phenotype and Oxidative Metabolism during Neonatal Skeletal Muscle Development\
(A--H) Neonatal muscle development.\
(A) SLN protein expression in neonatal quadriceps and gastrocnemius of WT mice.\
(B) The expression level of SERCA1a, SERCA2a, and calsequestrin 1 and 2 (CASQ1 and CASQ2) in 10-day-old WT and *Sln*-KO quadriceps muscle.\
(C) Decreased fatty acid (palmitoylcarnitine) oxidation in *Sln*-KO muscle. PC, palmitoylcarnitine; M, malate; Glut, glutamate; Succ, succinate (n = 5).\
(D) Decrease in mtDNA content.\
(E) Succinate dehydrogenase (SDH) activity staining in 10-day-old WT and *Sln*-KO quadriceps muscle.\
(F) Decreased expression of mitochondrial electron transport chain (ETC) proteins in *Sln*-KO muscle.\
(G) Decreased expression of enzymes involved in fat mobilization (LPL, lipoprotein lipase), fatty acid transport (CPT1-M, carnitine palmitoyltransferase-1 mitochondrial), β-oxidation enzymes (LCAD, long-chain acyl-CoA dehydrogenase; HADHB; 3-ketoacyl-CoA thiolase, acetyl-CoA acyltransferase, or beta-ke-tothiolase), adenine nucleotide translocator (ANT), and citrate synthase.\
(H) Upregulation of major glycolytic enzymes and higher levels of phosphorylated 5' adenosine monophosphate-activated protein (AMP) kinase (pAMPK) in *Sln*-KO muscle.\
(I--O) Adult soleus muscle from WT and *Sln*-KO mice.\
(I) mtDNA content is not altered in *Sln*-KO soleus.\
(J) ETC protein expression are unchanged.\
(K) *Sln*-KO soleus shows decreased expression of proteins involved in fat mobilization, fatty acid transport, β-oxidation enzymes, and citrate synthase.\
(L) Decreased fatty acid oxidation in *Sln*-KO soleus muscle. P, palmitoylCoA; C, carnitine; M, malate.\
(M) Levels of glycolytic enzymes are not altered.\
(N) SDH activity staining of adult WT and *Sln*-KO soleus muscle.\
(O) Immunostaining with myosin isoform-specific antibodies reveals that muscle fiber composition is not affected in the *Sln*-KO soleus muscle (n = 4). Yellow, myosin ATPase type I; red, myosin ATPase type IIa; green, myosin ATPase type IIb; black, myosin ATPase type x.\
Data are shown as mean ± SEM. \*p \< 0.01, \*\*p \< 0.001, \*\*\*p \< 0.0001, t test.](nihms-1507855-f0002){#F1}

![Transgenic Overexpression of SLN in Glycolytic Muscle (Tibialis Anterior) Programs Mitochondria to Increase Fatty Acid Metabolism and Protects from High-Fat Diet-Induced Lipotoxicity\
(A--D) WT and *Sln*^*OE*^ mice maintained on regular chow diet.\
(A) mtDNA copy number (n = 5).\
(B) ETC protein expression.\
(C) Expression level of fatty acid transporters (CD36 and CPT1-M), β-oxidation enzymes (LCAD and HADHB), ANT1/2, and TFAM in *Sln*^*OE*^ muscle is greater than in WT.\
(D) Increased fatty acid oxidation in *Sln*^*OE*^ muscle.\
(E--L) *Sln*^*OE*^, WT, and *Sln*-KO mice fed on a high-fat diet (HFD) for 12 weeks.\
(E) mtDNA copy number (n = 5).\
(F) ETC protein expression.\
(G) Regulators of oxidative metabolism.\
(H) Increased fatty acid oxidation in *Sln*^*OE*^ muscle oxidation (n = 5).\
(I) Oil red O staining of *Sln*^*OE*^ TA muscle shows no lipid accumulation.\
(J) Soleus muscle from *Sln*-KO mice showing increased lipid accumulation.\
(K) *Sln*^*OE*^ muscle shows lower levels of ceramides, DAG (diacylglyceride), and acylcarnitines (n = 4).\
(L) Higher rate of glucose uptake and clearance in TA muscle of *Sln*^*OE*^ mice (n = 5).\
Data are shown as mean ± SEM. \*p \< 0.01, \*\*p \< 0.001, \*\*\*p \< 0.0001, t test.](nihms-1507855-f0003){#F2}

![SLN Recruits PGC1α to Increase Mitochondrial Biogenesis\
(A) Primary muscle myotubes derived from satellite cell culture.\
(B) Protein levels of SLN during WT primary myotube differentiation.\
(C) Expression level of SLN and SR proteins, SERCA, and CASQ in primary myotubes.\
(D) mtDNA copy number.\
(E) Mitochondrial OXPHOS protein levels during myotube differentiation.\
(F) Fatty acid-stimulated oxygen consumption in myotubes.\
(G) Oxygen consumption rate (OCR) in *Sln*-KO myotubes.\
(H--J) Adenoviral SLN gene transfer rescued muscle mitochondrial content (H and I) and OCR (J) in *Sln*-KO myotubes.\
(K) PGC1α expression in WT and *Sln*-KO myotubes following adenoviral gene transfer.\
(L) PGC1α gene expression during WT and *Sln*-KO myotube differentiation.\
(M) Protein expression level of PGC1α, PPARδ, and TFAM in myotubes.\
(N--P) mtDNA copy number (N), ETC protein expression (O), and OCR (P) following knockdown of PGC1α and/or adenoviral SLN gene transfer in myotubes.\
(Q) Rescue of mtDNA content in *Sln*-KO myotubes by adenoviral PGC1α gene transfection.](nihms-1507855-f0004){#F3}

![SLN-Mediated Increase in Mitochondrial Biogenesis Depends on SR-Ca^2+^ Cycling, Activation of CamKII, and Recruitment of the PGC1α Axis\
(A) Adenoviral-mediated expression of SLN in myotubes.\
(B) Myoplasmic Ca^2+^ as detected by Fluo-4 signal after caffeine administration.\
(C) Ca^2+^ transients after activation with caffeine, as indicated by both time measurement (in seconds) and curve slope analysis (in int/ms).\
(D) Activation of SR-Ca^2+^ cycling by caffeine treatment (3.5 mM to promote SR-Ca^2+^ release) increases CamKII phosphorylation and Mef2c expression in WT myotubes.\
(E) Increased mtDNA content.\
(F) PGC1α expression in caffeine-treated WT myotubes.\
(G) Caffeine treatment induced expression of proteins involved in fatty acid metabolism in WT myotubes, but not in *Sln*-KO myotubes.\
(H) Caffeine increases OCR in WT myotubes.\
(I) In hibition of SR-Ca^2+^ cycling by dantrolene treatment (10 μM to block SR-Ca^2+^ release) decreased CamKII phosphorylation and Mef2c expression.\
(J) mtDNA content.\
(K) PGC1α expression followed by dantrolene treatment.\
(L) Dantrolene treatment decreased expression of mitochondrial transcriptional regulators and metabolic proteins.\
(M) OCR in myotubes.\
(N) Inhibition of CamKII activity by KN93 treatment (10 nM) decreased CamKII phosphorylation, whereas adenoviral SLN gene transfer in KO myotubes rescuedthe phosphorylation status in CamKII.\
(O and P) mtDNA content (O) and OCR (P) in myotubes following KN93 pretreatment.\
(Q) Schematic representation of how sarcolipin signals to increase mitochondrial biogenesis.](nihms-1507855-f0005){#F4}

###### Highlights

-   Sarcolipin (SLN) regulates thermogenesis and energy metabolism in skeletal muscle

-   Loss of SLN leads to obesity, whereas overexpression of SLN resists against obesity

-   SLN promotes mitochondrial biogenesis and oxidative phenotype in glycolytic muscle

-   SLN activates the CamKII-PGC1α signaling pathway to promote mitochondrial biogenesis
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